{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:42:22Z","timestamp":1792590142702,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"DOI":"10.1007\/s40123-026-01496-w","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:11:48Z","timestamp":1792584708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient and Physician Perspectives on Oral Treatment in Ophthalmology"],"prefix":"10.1007","author":[{"given":"Jill","family":"Adelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Udaondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Garh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Csaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"1496_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s11892-022-01491-y","volume":"22","author":"JA Zehden","year":"2022","unstructured":"Zehden JA, Mortensen XM, Reddy A, Zhang AY. Systemic and ocular adverse events with intravitreal anti-VEGF therapy used in the treatment of diabetic retinopathy: a review. Curr Diab Rep. 2022;22:525\u201336.","journal-title":"Curr Diab Rep"},{"key":"1496_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/OPTH.S409103","volume":"17","author":"G Reitan","year":"2023","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesboll C. Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway. Clin Ophthalmol. 2023;17:1465\u201374.","journal-title":"Clin Ophthalmol"},{"key":"1496_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14712598.2022.2100694","volume":"22","author":"G Uludag","year":"2022","unstructured":"Uludag G, Hassan M, Matsumiya W, et al. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? Expert Opin Biol Ther. 2022;22:1275\u201391.","journal-title":"Expert Opin Biol Ther"},{"key":"1496_CR4","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.drudis.2019.05.035","volume":"24","author":"FJ Cabrera","year":"2019","unstructured":"Cabrera FJ, Wang DC, Reddy K, Acharya G, Shin CS. Challenges and opportunities for drug delivery to the posterior of the eye. Drug Discov Today. 2019;24:1679\u201384.","journal-title":"Drug Discov Today"},{"key":"1496_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081140","volume":"16","author":"A Hang","year":"2023","unstructured":"Hang A, Feldman S, Amin AP, Ochoa JAR, Park SS. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals (Basel). 2023;16:1140.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1496_CR6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.14.46","volume":"65","author":"KL Huber","year":"2024","unstructured":"Huber KL, Stino H, Steiner I, et al. Real-world outcomes after switch from aflibercept to faricimab in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2024;65:46.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1496_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4274\/tjo.28003","volume":"47","author":"O Polat","year":"2017","unstructured":"Polat O, Inan S, Ozcan S, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk Oftalmol Derg. 2017;47:205\u201310.","journal-title":"Turk Oftalmol Derg"},{"key":"1496_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069625","volume":"13","author":"C Yiallouridou","year":"2023","unstructured":"Yiallouridou C, Acton JH, Banerjee S, Waterman H, Wood A. Pain related to intravitreal injections for age-related macular degeneration: a qualitative study of the perspectives of patients and practitioners. BMJ Open. 2023;13:e069625.","journal-title":"BMJ Open"},{"key":"1496_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/aos.15783","volume":"102","author":"E Vinge","year":"2024","unstructured":"Vinge E, Bro T. Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration. Acta Ophthalmol. 2024;102:478\u201382.","journal-title":"Acta Ophthalmol"},{"key":"1496_CR10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N, et al. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258:2077\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1496_CR11","first-page":"1260","volume":"27","author":"A Almony","year":"2021","unstructured":"Almony A, Keyloun KR, Shah-Manek B, et al. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. J Manag Care Spec Pharm. 2021;27:1260\u201372.","journal-title":"J Manag Care Spec Pharm"},{"key":"1496_CR12","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1007\/s10792-021-01906-x","volume":"41","author":"JM Ruiz-Moreno","year":"2021","unstructured":"Ruiz-Moreno JM, Arias L, Abraldes MJ, Montero J, Udaondo P, The Ramdeburs study group. Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. Int Ophthalmol. 2021;41:3427\u201336.","journal-title":"Int Ophthalmol"},{"key":"1496_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Felfeli T, Bogdanova-Bennet A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2024;8:537\u201344.","journal-title":"Ophthalmol Retina"},{"key":"1496_CR14","doi-asserted-by":"publisher","first-page":"7345","DOI":"10.3390\/jcm14207345","volume":"14","author":"J Kucharczuk","year":"2025","unstructured":"Kucharczuk J, Kasprzak H, Gawecki M. Switching from aflibercept to faricimab in the treatment of neovascular age-related macular degeneration: short-term results from real-life study. J Clin Med. 2025;14:7345.","journal-title":"J Clin Med"},{"key":"1496_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","volume":"58","author":"W Kiddee","year":"2013","unstructured":"Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58:291\u2013310.","journal-title":"Surv Ophthalmol"},{"key":"1496_CR16","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1007\/s00417-023-06134-w","volume":"261","author":"SN Chen","year":"2023","unstructured":"Chen SN, Chen SJ, Wu TT, Wu WC, Yang CH, Yang CM. Refining vitrectomy for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2023;261:3659\u201370.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1496_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11892-021-01403-6","volume":"21","author":"LA Everett","year":"2021","unstructured":"Everett LA, Paulus YM. Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2021;21:35.","journal-title":"Curr Diab Rep"},{"key":"1496_CR18","volume":"14","author":"GS Pande","year":"2022","unstructured":"Pande GS, Tidake P. Laser treatment modalities for diabetic retinopathy. Cureus. 2022;14:e30024.","journal-title":"Cureus"},{"key":"1496_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00592-020-01513-9","volume":"57","author":"F Fajnkuchen","year":"2020","unstructured":"Fajnkuchen F, Delyfer MN, Conrath J, et al. Expectations and fears of patients with diabetes and macular edema treated by intravitreal injections. Acta Diabetol. 2020;57:1081\u201391.","journal-title":"Acta Diabetol"},{"key":"1496_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00417-021-05359-x","volume":"260","author":"SW Quist","year":"2022","unstructured":"Quist SW, de Jong LA, van Asten F, Knoester P, Postma MJ, Freriks RD. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022;260:1083\u201395.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1496_CR21","first-page":"244","volume":"42","author":"E Cervera","year":"2018","unstructured":"Cervera E, De Andres-Nogales F, Armada F, Arias L, Oyaguez I, Martinez C. Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema. Farm Hosp. 2018;42:244\u201350.","journal-title":"Farm Hosp"},{"key":"1496_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001188","volume":"7","author":"R Wang","year":"2022","unstructured":"Wang R, McClard CK, Laswell S, et al. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmol. 2022;7:e001188.","journal-title":"BMJ Open Ophthalmol"},{"key":"1496_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939\u201346.","journal-title":"Clin Ophthalmol"},{"key":"1496_CR24","volume":"9","author":"JR Evans","year":"2023","unstructured":"Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023;9:CD000254.","journal-title":"Cochrane Database Syst Rev"},{"key":"1496_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-024-05596-9","volume":"24","author":"F Uzun","year":"2024","unstructured":"Uzun F. Clinical characteristics and intravitreal aflibercept outcomes in patients aged 90 years and older with neovascular age-related macular degeneration. BMC Geriatr. 2024;24:1003.","journal-title":"BMC Geriatr"},{"key":"1496_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/ICU.0000000000000948","volume":"34","author":"CMT DeBoer","year":"2023","unstructured":"DeBoer CMT, Agrawal R, Rahimy E. Novel oral medications for retinal disease: an update on clinical development. Curr Opin Ophthalmol. 2023;34:203\u201310.","journal-title":"Curr Opin Ophthalmol"},{"key":"1496_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98568-7","volume":"11","author":"B Jacobs","year":"2021","unstructured":"Jacobs B, Palmer N, Shetty T, et al. Patient preferences in retinal drug delivery. Sci Rep. 2021;11:18996.","journal-title":"Sci Rep"},{"key":"1496_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Auregan","year":"2022","unstructured":"Giocanti-Auregan A, Garcia-Layana A, Peto T, et al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence. 2022;16:587\u2013604.","journal-title":"Patient Prefer Adherence"},{"key":"1496_CR29","first-page":"S2","volume":"29","author":"SJ Bakri","year":"2023","unstructured":"Bakri SJ, Bektas M, Sharp D, Luo R, Sarda SP, Khan S. Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system. J Manag Care Spec Pharm. 2023;29:S2\u201311.","journal-title":"J Manag Care Spec Pharm"},{"key":"1496_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049495","volume":"11","author":"J Enoch","year":"2021","unstructured":"Enoch J, Ghulakhszian A, Crabb DP, Dinah C, Taylor DJ. Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study. BMJ Open. 2021;11:e049495.","journal-title":"BMJ Open"},{"key":"1496_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/OPTH.S445755","volume":"18","author":"CD Regillo","year":"2024","unstructured":"Regillo CD, Nijm LM, Shechtman DL, et al. Considerations for the identification and management of geographic atrophy: recommendations from an expert panel. Clin Ophthalmol. 2024;18:325\u201335.","journal-title":"Clin Ophthalmol"},{"key":"1496_CR32","volume":"14","author":"H Vyawahare","year":"2022","unstructured":"Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14:e29583.","journal-title":"Cureus"},{"key":"1496_CR33","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.jfma.2021.06.012","volume":"120","author":"L Yeung","year":"2021","unstructured":"Yeung L, Hsieh Y-T, Yang C-H, et al. Management of neovascular age-related macular degeneration: Taiwan expert consensus. J Formos Med Assoc. 2021;120:2061\u201371.","journal-title":"J Formos Med Assoc"},{"key":"1496_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s41687-024-00775-z","volume":"8","author":"AM Kubin","year":"2024","unstructured":"Kubin AM, Korva-Gurung I, Ohtonen P, Hautala N. Health-related quality of life in patients with neovascular age-related macular degeneration: a prospective cohort study. J Patient Rep Outcomes. 2024;8:89.","journal-title":"J Patient Rep Outcomes"},{"key":"1496_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1089\/tmj.2017.0282","volume":"25","author":"P Romero-Aroca","year":"2018","unstructured":"Romero-Aroca P, Valls A, Moreno A, et al. A clinical decision support system for diabetic retinopathy screening: creating a clinical support application. Telemed J E Health. 2018;25:31\u201340.","journal-title":"Telemed J E Health"},{"key":"1496_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaophthalmol.2023.6435","volume":"142","author":"MG Zayed","year":"2024","unstructured":"Zayed MG, Karsan W, Peto T, Saravanan P, Virgili G, Preiss D. Diabetic retinopathy and quality of life: a systematic review and meta-analysis. JAMA Ophthalmol. 2024;142:199\u2013207.","journal-title":"JAMA Ophthalmol"},{"key":"1496_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98488-6","volume":"11","author":"C-C Kao","year":"2021","unstructured":"Kao C-C, Hsieh H-M, Lee DY, Hsieh K-P, Sheu S-J. Importance of medication adherence in treatment needed diabetic retinopathy. Sci Rep. 2021;11:19100.","journal-title":"Sci Rep"},{"key":"1496_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1077669","volume":"13","author":"TE Tan","year":"2030","unstructured":"Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030. Front Endocrinol (Lausanne). 2030;13:1077669.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1496_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/diabetology3010011","volume":"3","author":"P Ansari","year":"2022","unstructured":"Ansari P, Tabasumma N, Snigdha NN, et al. Diabetic retinopathy: an overview on mechanisms, pathophysiology and pharmacotherapy. Diabetologia. 2022;3:159\u201375.","journal-title":"Diabetologia"},{"key":"1496_CR40","unstructured":"American Academy of Ophthalmology. Summary benchmarks - full set - 2024. 2024. https:\/\/www.aao.org\/education\/summary-benchmark-detail\/summary-benchmarks-full-set-2020. Accessed 22 Jan 2026"},{"key":"1496_CR41","unstructured":"Apellis Pharmaceuticals Inc. FDA approves SYFOVRE\u2122 (pegcetacoplan injection) as the first and only treatment for geographic atrophy (GA), a leading cause of blindness. 2023. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only. Accessed 21 Nov 2025"},{"key":"1496_CR42","unstructured":"Astellas Pharma US Inc. IZERVAY\u2122 (avacincaptad pegol intravitreal solution) showed increased benefit in reducing geographic atrophy progression over time and consistent long-term safety. 2025. https:\/\/newsroom.astellas.com\/2025-10-19-IZERVAY-TM-avacincaptad-pegol-intravitreal-solution-Showed-Increased-Benefit-in-Reducing-Geographic-Atrophy-Progression-Over-Time-and-Consistent-Long-Term-Safety. Accessed 19 Nov 2025"},{"key":"1496_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/aos.14377","volume":"98","author":"AS Elkjaer","year":"2020","unstructured":"Elkjaer AS, Lynge SK, Grauslund J. Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review. Acta Ophthalmol. 2020;98:329\u201336.","journal-title":"Acta Ophthalmol"},{"key":"1496_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58121741","volume":"58","author":"JB Vasilijevi\u0107","year":"2022","unstructured":"Vasilijevi\u0107 JB, Kova\u010devi\u0107 IM, Bukumiri\u0107 ZM, Mari\u0107 GD, Slijep\u010devi\u0107 NA, Pekmezovi\u0107 TD. Vision-related quality of life and treatment satisfaction following panretinal photocoagulation in diabetic retinopathy-a panel study. Medicina (Kaunas). 2022;58:1741.","journal-title":"Medicina (Kaunas)"},{"key":"1496_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40123-022-00614-8","volume":"12","author":"SA Sherman","year":"2023","unstructured":"Sherman SA, Rofail D, Levine A, et al. The patient experience with diabetic retinopathy: qualitative analysis of patients with proliferative diabetic retinopathy. Ophthalmol Ther. 2023;12:431\u201346.","journal-title":"Ophthalmol Ther"},{"key":"1496_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100318","volume":"3","author":"E Rahimy","year":"2023","unstructured":"Rahimy E, Khan MA, Ho AC, et al. Progression of geographic atrophy: retrospective analysis of patients from the IRIS\u00ae registry (Intelligent Research in Sight). Ophthalmol Sci. 2023;3:100318.","journal-title":"Ophthalmol Sci"},{"key":"1496_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56309-6","volume":"14","author":"J Jung","year":"2024","unstructured":"Jung J, Han J, Han JM, et al. Prediction of neovascular age-related macular degeneration recurrence using optical coherence tomography images with a deep neural network. Sci Rep. 2024;14:5854.","journal-title":"Sci Rep"},{"key":"1496_CR48","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_480_21","author":"BAM Mounirou","year":"2022","unstructured":"Mounirou BAM, Adam ND, Yakoura AKH, Aminou MSM, Liu YT, Tan LY. Diabetic retinopathy: an overview of treatments. Indian J Endocrinol Metab. 2022. https:\/\/doi.org\/10.4103\/ijem.ijem_480_21.","journal-title":"Indian J Endocrinol Metab"},{"key":"1496_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001395","volume":"8","author":"KK Peter","year":"2023","unstructured":"Peter KK, Paul MK, Carl DR, et al. Geographic Atrophy Management Consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment. BMJ Open Ophthalmol. 2023;8:e001395.","journal-title":"BMJ Open Ophthalmol"},{"key":"1496_CR50","first-page":"513","volume":"117","author":"A Stahl","year":"2020","unstructured":"Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117:513\u20139.","journal-title":"Dtsch Arztebl Int"},{"key":"1496_CR51","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","volume":"121","author":"FG Holz","year":"2014","unstructured":"Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren CM. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121:1079\u201391.","journal-title":"Ophthalmology"},{"key":"1496_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/OPTH.S226425","volume":"14","author":"PJ Patel","year":"2020","unstructured":"Patel PJ, Ziemssen F, Ng E, et al. Burden of illness in geographic atrophy: a study of vision-related quality of life and health care resource use. Clin Ophthalmol. 2020;14:15\u201328.","journal-title":"Clin Ophthalmol"},{"key":"1496_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40942-023-00493-6","volume":"9","author":"B Antonio-Aguirre","year":"2023","unstructured":"Antonio-Aguirre B, Arevalo JF. Treating patients with geographic atrophy: Are we there yet? Int J Retina Vitreous. 2023;9:72.","journal-title":"Int J Retina Vitreous"},{"key":"1496_CR54","unstructured":"American Society of Retina Specialists. 2025 preferences and trends survey results. 2025. https:\/\/www.asrs.org\/asrs-community\/pat-survey\/results-new\/1078?evergreen=staff"},{"key":"1496_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.oret.2020.12.009","volume":"5","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe GJ, Chakravarthy U, Freund KB, et al. Imaging features associated with progression to geographic atrophy in age-related macular degeneration: classification of Atrophy Meeting Report 5. Ophthalmol Retina. 2021;5:855\u201367.","journal-title":"Ophthalmol Retina"},{"key":"1496_CR56","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1007\/s12325-025-03219-2","volume":"42","author":"LJ Faia","year":"2025","unstructured":"Faia LJ, Ackert J, Rodriguez R, et al. Comorbid depression and anxiety risk in older individuals with geographic atrophy: a US claims data analysis. Adv Ther. 2025;42:3826\u201338.","journal-title":"Adv Ther"},{"key":"1496_CR57","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/01.icu.0001276628.01684.a6","volume":"17","author":"MM Brown","year":"2006","unstructured":"Brown MM, Brown GC, Sharma S, et al. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006;17:257\u201366.","journal-title":"Curr Opin Ophthalmol"},{"key":"1496_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12886-023-02901-9","volume":"23","author":"DL Holm","year":"2023","unstructured":"Holm DL, Nielsen MK, Hojsted BB, Sorensen TL. Vision-related quality of life is selectively affected by comorbidities in patients with geographic atrophy. BMC Ophthalmol. 2023;23:153.","journal-title":"BMC Ophthalmol"},{"key":"1496_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047861","volume":"11","author":"G Madheswaran","year":"2021","unstructured":"Madheswaran G, Ramesh SV, Pardhan S, Sapkota R, Raman R. Impact of living with a bilateral central vision loss due to geographic atrophy\u2014Qualitative study. BMJ Open. 2021;11:e047861.","journal-title":"BMJ Open"},{"key":"1496_CR60","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41433-019-0445-8","volume":"34","author":"DJ Taylor","year":"2020","unstructured":"Taylor DJ, Jones L, Binns AM, Crabb DP. \u2018You\u2019ve got dry macular degeneration, end of story\u2019: a qualitative study into the experience of living with non-neovascular age-related macular degeneration. Eye (Lond). 2020;34:461\u201373.","journal-title":"Eye (Lond)"},{"key":"1496_CR61","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/aos.15794","volume":"101","author":"M Krogh Nielsen","year":"2023","unstructured":"Krogh Nielsen M, Hinnerskov JMV, Sorensen TL. Geographic atrophy - Signs, symptoms, and quality of life. Acta Ophthalmol. 2023;101:896\u2013902.","journal-title":"Acta Ophthalmol"},{"key":"1496_CR62","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.2147\/OPTH.S488559","volume":"18","author":"SJ Bakri","year":"2024","unstructured":"Bakri SJ, Brinkmann CK, Mulvey A, et al. Characterizing patient perceptions of living with geographic atrophy: the global geographic atrophy insights survey. Clin Ophthalmol. 2024;18:3725\u201337.","journal-title":"Clin Ophthalmol"},{"key":"1496_CR63","unstructured":"Astellas Pharma US Inc. Astellas receives conditional approval for IZERVAY, making it the first and only approved treatment for the suppression of geographic atrophy growth in Japan. 2025. https:\/\/newsroom.astellas.com\/2025-09-19-Astellas-Receives-Conditional-Approval-for-IZERVAY,-making-it-the-first-and-only-approved-treatment-for-the-Suppression-of-Geographic-Atrophy-Growth-in-Japan. Accessed 18 Nov 2025"},{"key":"1496_CR64","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/IAE.0000000000003796","volume":"43","author":"RF Spaide","year":"2023","unstructured":"Spaide RF, Vavvas DG. Complement inhibition for geographic atrophy: review of salient functional outcomes and perspective. Retina. 2023;43:1064\u20139.","journal-title":"Retina"},{"key":"1496_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21:133.","journal-title":"J Transl Med"},{"key":"1496_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031170","volume":"22","author":"A Pugazhendhi","year":"2021","unstructured":"Pugazhendhi A, Hubbell M, Jairam P, Ambati B. Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy. Int J Mol Sci. 2021;22:1170.","journal-title":"Int J Mol Sci"},{"key":"1496_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0514-3","volume":"17","author":"M Elshout","year":"2017","unstructured":"Elshout M, Webers CA, van der Reis MI, de Jong-Hesse Y, Schouten JS. Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study. BMC Ophthalmol. 2017;17:120.","journal-title":"BMC Ophthalmol"},{"key":"1496_CR68","first-page":"311","volume":"67","author":"N Holekamp","year":"2024","unstructured":"Holekamp N, Gentile B, Giocanti-Auregan A, et al. Patient experience survey of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration and diabetic macular edema. Ophthalmic Res. 2024;67:311\u201321.","journal-title":"Ophthalmic Res"},{"key":"1496_CR69","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/13548506.2014.936886","volume":"20","author":"J Boyle","year":"2015","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C. Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review. Psychol Health Med. 2015;20:296\u2013310.","journal-title":"Psychol Health Med"},{"key":"1496_CR70","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/eye.2015.167","volume":"29","author":"C McCloud","year":"2015","unstructured":"McCloud C, Lake S. Understanding the patient\u2019s lived experience of neovascular age-related macular degeneration: a qualitative study. Eye (Lond). 2015;29:1561\u20139.","journal-title":"Eye (Lond)"},{"key":"1496_CR71","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41433-021-01470-9","volume":"36","author":"E Midena","year":"2022","unstructured":"Midena E, Varano M, Pilotto E, et al. Real-life patient journey in neovascular age-related macular degeneration: a narrative medicine analysis in the Italian setting. Eye (Lond). 2022;36:182\u201392.","journal-title":"Eye (Lond)"},{"key":"1496_CR72","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.survophthal.2024.03.002","volume":"69","author":"M Scheffer","year":"2024","unstructured":"Scheffer M, Menting J, Boeije H, van Nispen R, van Dulmen S. Understanding healthcare communication in age-related macular degeneration care: a mixed-methods review of patients\u2019 perspectives. Surv Ophthalmol. 2024;69:646\u201360.","journal-title":"Surv Ophthalmol"},{"key":"1496_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/aos.16777","volume":"103","author":"M Scheffer","year":"2025","unstructured":"Scheffer M, Menting J, Rausch-Koster P, van Nispen R, van Dulmen S. Looking beyond the eyes of the patient: the importance of effective communication in the treatment of age-related macular degeneration. Acta Ophthalmol. 2025;103:205\u201314.","journal-title":"Acta Ophthalmol"},{"key":"1496_CR74","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128:1580\u201391.","journal-title":"Ophthalmology"},{"key":"1496_CR75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-023-00314-8","volume":"14","author":"M Kropp","year":"2023","unstructured":"Kropp M, Golubnitschaja O, Mazurakova A, et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation. EPMA J. 2023;14:21\u201342.","journal-title":"EPMA J"},{"key":"1496_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061816","volume":"19","author":"W Wang","year":"2018","unstructured":"Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19:1816.","journal-title":"Int J Mol Sci"},{"key":"1496_CR77","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/bjophthalmol-2017-310664","volume":"102","author":"G Staurenghi","year":"2018","unstructured":"Staurenghi G, Feltgen N, Arnold JJ, et al. Impact of baseline diabetic retinopathy severity scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Br J Ophthalmol. 2018;102:954\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1496_CR78","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","volume":"110","author":"CP Wilkinson","year":"2003","unstructured":"Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677\u201382.","journal-title":"Ophthalmology"},{"key":"1496_CR79","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40662-022-00286-2","volume":"9","author":"R Han","year":"2022","unstructured":"Han R, Gong R, Liu W, Xu G. Optical coherence tomography angiography metrics in different stages of diabetic macular edema. Eye Vis (Lond). 2022;9:14.","journal-title":"Eye Vis (Lond)"},{"key":"1496_CR80","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.11.19","volume":"65","author":"A Ruffini","year":"2024","unstructured":"Ruffini A, Dvoriashyna M, Govetto A, Romano MR, Repetto R. A mathematical model of interstitial fluid flow and retinal tissue deformation in macular edema. Invest Ophthalmol Vis Sci. 2024;65:19.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1496_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019236","volume":"99","author":"L Yin","year":"2020","unstructured":"Yin L, Zhang D, Ren Q, Su X, Sun Z. Prevalence and risk factors of diabetic retinopathy in diabetic patients: a community based cross-sectional study. Medicine (Baltimore). 2020;99:e19236.","journal-title":"Medicine (Baltimore)"},{"key":"1496_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12912-023-01206-y","volume":"22","author":"M Zhang","year":"2023","unstructured":"Zhang M, Zhang C, Chen C, et al. The experience of diabetic retinopathy patients during hospital-to-home full-cycle care: a qualitative study. BMC Nurs. 2023;22:58.","journal-title":"BMC Nurs"},{"key":"1496_CR83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12955-025-02340-8","volume":"23","author":"N Purohit","year":"2025","unstructured":"Purohit N, Goyal A, Gupta V, Gupta PC, Singh P, Prinja S. Measuring the quality of life of patients with diabetic retinopathy in northern India: a comparison of generic and vision specific instruments. Health Qual Life Outcomes. 2025;23:17.","journal-title":"Health Qual Life Outcomes"},{"key":"1496_CR84","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1055\/s-0035-1556731","volume":"41","author":"N Murugesan","year":"2015","unstructured":"Murugesan N, Ustunkaya T, Feener EP. Thrombosis and hemorrhage in diabetic retinopathy: a perspective from an inflammatory standpoint. Semin Thromb Hemost. 2015;41:659\u201364.","journal-title":"Semin Thromb Hemost"},{"key":"1496_CR85","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s11136-012-0110-1","volume":"21","author":"EK Fenwick","year":"2012","unstructured":"Fenwick EK, Pesudovs K, Khadka J, et al. The impact of diabetic retinopathy on quality of life: qualitative findings from an item bank development project. Qual Life Res. 2012;21:1771\u201382.","journal-title":"Qual Life Res"},{"key":"1496_CR86","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ajo.2008.02.006","volume":"145","author":"F Okamoto","year":"2008","unstructured":"Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function following vitrectomy for proliferative diabetic retinopathy. Am J Ophthalmol. 2008;145:1031\u20136.","journal-title":"Am J Ophthalmol"},{"key":"1496_CR87","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/PPA.S106629","volume":"10","author":"D Eek","year":"2016","unstructured":"Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609\u201321.","journal-title":"Patient Prefer Adherence"},{"key":"1496_CR88","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1007\/s11255-024-04028-2","volume":"56","author":"HC Wong","year":"2024","unstructured":"Wong HC, Cheung BC, Yuen VW, Teoh JY, Chiu PK, Ng CF. Patient preference on once-daily oral versus injectable androgen deprivation therapy for Asian patients with advanced prostate cancer. Int Urol Nephrol. 2024;56:2923\u20138.","journal-title":"Int Urol Nephrol"},{"issue":"Suppl 3","key":"1496_CR89","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","volume":"6","author":"SN Weingart","year":"2008","unstructured":"Weingart SN, Brown E, Bach PB, et al. NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):S1\u201314.","journal-title":"J Natl Compr Canc Netw"},{"key":"1496_CR90","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1188\/14.ONF.41-02AP","volume":"41","author":"JC Roop","year":"2014","unstructured":"Roop JC, Wu HS. Current practice patterns for oral chemotherapy: results of a national survey. Oncol Nurs Forum. 2014;41:185\u201394.","journal-title":"Oncol Nurs Forum"},{"key":"1496_CR91","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ejon.2011.10.002","volume":"16","author":"L Wood","year":"2012","unstructured":"Wood L. A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs. 2012;16:432\u20138.","journal-title":"Eur J Oncol Nurs"},{"key":"1496_CR92","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.2146\/ajhp070037","volume":"64","author":"CS Viele","year":"2007","unstructured":"Viele CS. Managing oral chemotherapy: the healthcare practitioner\u2019s role. Am J Health Syst Pharm. 2007;64:S25\u201332.","journal-title":"Am J Health Syst Pharm"},{"key":"1496_CR93","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1188\/03.CJON.S6.5-9","volume":"7","author":"CH Bedell","year":"2003","unstructured":"Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2003;7:5\u20139.","journal-title":"Clin J Oncol Nurs"},{"key":"1496_CR94","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/17512433.2023.2279740","volume":"16","author":"P Munoz-Villegas","year":"2023","unstructured":"Munoz-Villegas P, Martinez-Bautista H, Olvera-Montano O. Determinants of adherence to treatment in patients with ophthalmic conditions. Expert Rev Clin Pharmacol. 2023;16:1249\u201359.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1496_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ph16050646","volume":"16","author":"E Lucenteforte","year":"2023","unstructured":"Lucenteforte E, Finocchietti M, Addis A, et al. Polytherapy and multimorbidity pattern of users of anti-VEGF drugs and dexamethasone for the treatment of age-related macular degeneration and other vascular retinopathies in clinical practice. Pharmaceuticals (Basel). 2023;16:646.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1496_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12123960","volume":"12","author":"RM Alhumaidi","year":"2023","unstructured":"Alhumaidi RM, Bamagous GA, Alsanosi SM, et al. Risk of polypharmacy and its outcome in terms of drug interaction in an elderly population: a retrospective cross-sectional study. J Clin Med. 2023;12:3960.","journal-title":"J Clin Med"},{"key":"1496_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78236-y","volume":"10","author":"YA Weng","year":"2020","unstructured":"Weng YA, Deng CY, Pu C. Targeting continuity of care and polypharmacy to reduce drug-drug interaction. Sci Rep. 2020;10:21279.","journal-title":"Sci Rep"},{"key":"1496_CR98","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11096-014-9925-x","volume":"36","author":"P Cornu","year":"2014","unstructured":"Cornu P, Steurbaut S, So\u0161tari\u0107 S, Mrhar A, Dupont AG. Performance of a clinical decision support system and of clinical pharmacists in preventing drug-drug interactions on a geriatric ward. Int J Clin Pharm. 2014;36:519\u201325.","journal-title":"Int J Clin Pharm"},{"key":"1496_CR99","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/s41433-023-02409-y","volume":"37","author":"S Sivaprasad","year":"2023","unstructured":"Sivaprasad S, Ghanchi F, Kelly SP, et al. Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes. Eye (Lond). 2023;37:2753\u201360.","journal-title":"Eye (Lond)"},{"key":"1496_CR100","unstructured":"American Academy of Ophthalmology. Intravitreal injections. 2025. 202. https:\/\/www.aao.org\/education\/clinical-statement\/intravitreal-injections-statement. Accessed 17 Mar 2026"},{"key":"1496_CR101","unstructured":"Astellas Pharma US Inc. China\u2019s National Medical Products Administration accepts new drug application for IZERVAY\u2122 (avacincaptad pegol) for the treatment of geographic atrophy secondary to age-related macular degeneration. 2026. https:\/\/newsroom.astellas.com\/2026-05-15-chinas-nmpa-accepts-ndapplication-for-izervay-for-the-treatment-of-geographic-atrophy-secondary-to-age-related-macular-degeneration. Accessed 15 July 2026"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01496-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01496-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01496-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:02:59Z","timestamp":1792587779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01496-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":101,"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01496-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Karl Csaky has received grant clinical research contracts from Alexion, Astellas, Genentech\/Roche, Janssen\/Johnson & Johnson, and NGM Biopharmaceuticals; was a consultant for AbbVie, Annexon Biosciences, Boehringer Ingelheim, EyeBio, Genentech\/Roche, Janssen\/Johnson & Johnson, Merck, NGM Biopharmaceuticals, Novartis and Regeneron; received payment for expert testimony from Genentech and Regeneron; has a patent issued with Two Layer Episcleral Drug Delivery Implant; and has stock or stock options with Vinci Pharmaceuticals, Inc. Gerhard Garh\u00f6fer was a consultant for Active Biotech, Bausch & Lomb, Boehringer Ingelheim, Croma, Eleva, Horus, Imagine Eyes, Inventiva, Ocubio, ORA, Santen, and Thea. Patricia Udaondo was a consultant for AbbVie, Alcon, Alimera, Bayer, Boehringer Ingelheim, Brill, EyePoint, Ocular Therapeutix, Roche and Sandoz; and lectures for AbbVie, Alimera, Bausch and Lomb, Bayer, Boehringer Ingelheim, Roche, and Topcon. Margaret Mason, Bill Best, Jill Adelman, Rory Fisher, and Randall Barker have no financial disclosures to report.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}